• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    FDA Accepts IND for Dogwood Therapeutics’s SP16 Pain Therapy

    GLOBENEWSWIRE

    Dogwood Therapeutics Reveals 2025 Financial Performance

    GLOBENEWSWIRE

    Dogwood Therapeutics Ongoing Halneuron Trial at 50%; Top Results

    GLOBENEWSWIRE

    Dogwood Enrolls First 100 Patients In Halneuron(R) Ph 2B Trial

    PHARMIWEB

    Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

    GLOBENEWSWIRE

    Dogwood Therapeutics To Release Q3 2025 Financial Results

    PHARMIWEB

    Dogwood Therapeutics To Attend Maxim Growth Summit 2025

    PHARMIWEB

    Dogwood CMO To Present Halneuron Pain Program at Confernce

    PHARMIWEB

    Dogwood Secures License for SP16 in Cancer Pain Treatment

    GLOBENEWSWIRE

    Dogwood Therapeutics enrolls first fifty patients in Halneuron®

    GLOBENEWSWIRE

    Dogwood Therapeutics to Report Q2 2025 Financial Results

    GLOBENEWSWIRE

    Dogwood Therapeutics at Sidoti Small-Cap Virtual Conference

    GLOBENEWSWIRE

    Dogwood Therapeutics Doses First Patient in Halneuron® Trial

    GLOBENEWSWIRE

    Dogwood Therapeutics Announces Low Dose IMC-2 Reduces Long-COVID

    GLOBENEWSWIRE

    Dogwood Therapeutics Announces Q3 2024 Financial Results

    GLOBENEWSWIRE

    Virios Therapeutics Announces Second Quarter 2024 Financial Results

    GLOBENEWSWIRE

    Virios Completes Enrollment In IMC-2 Phase 2 Long-COVID Study

    GLOBENEWSWIRE

    Virios Closes $1.7M Offering To Prep IMC-2 Long COVID Study

    GLOBENEWSWIRE

    Virios Prices $1.7M Offering For Long-COVID Phase 2b Prep

    GLOBENEWSWIRE

    Virios Announces Proposed Offering For Long-COVID Phase 2b Prep

    GLOBENEWSWIRE

    Virios Announces Publication of International Patent for Treatment of Long-COVID

    GLOBENEWSWIRE

    Virios Announces Data Demonstrating Improvement in Multiple Long-COVID Symptoms

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.